Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 18, 2019
Reporting Period: The filing serves as a cover document for the notification of Q2 FY2020 results (Exhibit 99.1). The registrant is an Irish-domiciled company with principal executive offices in Dublin.
Key Financial Metrics
The provided text is a cover filing and does not contain specific financial data. The filing references "Q2 FY2020 Results notification" as Exhibit 99.1, but the numerical values for revenue, profit, cash flow, margins, debt, or liquidity are not present in the source text.
Material Changes
The filing text does not provide specific comparative financial data or details on material changes versus the prior period. It references the Q2 FY2020 results notification separately.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document contains an extensive disclaimer regarding forward-looking statements. These include projections on future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks Identified:
- Asbestos Liabilities: Risks related to prior asbestos manufacturing, contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls in the AICF, and currency exchange impacts on asbestos liabilities.
- Legal and Regulatory: Exposure to product liability, environmental, consumer class action, and intellectual property proceedings.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, consumer confidence, and mortgage availability.
- Operational: Supply and cost of raw materials, competition, and the integration of Fermacell into the business.
- Financial: Currency exchange risks and the potential inability to renew credit facilities on favorable terms.
Investor Verification Checklist
- Review Exhibit 99.1 (Q2 FY2020 Results notification) for actual financial performance data, as it is not included in this cover filing.
- Verify the status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF) and any recent changes to contribution estimates.
- Monitor the integration progress of the Fermacell acquisition and its impact on operational costs.
- Assess current housing market conditions in the US and Asia Pacific regions, given the company's dependence on residential and commercial construction.
- Check for updates on credit facility terms and covenants, particularly regarding renewal expectations.